Earnings ·
AbbVie updated its 2025 guidance to include an expected $2.7 billion pre-tax charge for acquired IPR&D and milestone…
ABBVAbbVie Inc.
AbbVie updated its 2025 guidance to include an expected $2.7 billion pre-tax charge for acquired IPR&D and milestone expenses in the third quarter, which will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $1.50. This results in a revised full-year 2025 adjusted diluted EPS guidance range of $10.38 to $10.58. The update is significant for investors as it quantifies the impact of substantial, non-recurring acquisition-related costs that were previously excluded from the company's earnings outlook.